Compare MDWD & MRLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDWD | MRLN |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.2M | 172.8M |
| IPO Year | 2013 | 2024 |
| Metric | MDWD | MRLN |
|---|---|---|
| Price | $11.96 | $0.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $30.67 | $7.92 |
| AVG Volume (30 Days) | 79.3K | ★ 2.9M |
| Earning Date | 11-19-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.60 | $9.23 |
| Revenue Next Year | $34.34 | $153.29 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.84 | $0.82 |
| 52 Week High | $19.70 | $17.00 |
| Indicator | MDWD | MRLN |
|---|---|---|
| Relative Strength Index (RSI) | 39.47 | 21.73 |
| Support Level | $11.84 | N/A |
| Resistance Level | $14.06 | $3.45 |
| Average True Range (ATR) | 0.50 | 0.12 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 11.54 | 7.48 |
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Merlin Inc develops software that fulfills the functions of a human pilot in self-flying aircraft to enable both reduced crew and unmanned flight. This technology is designed to be scalable and adaptable across different aircraft types for a growing range of aircraft platforms. The company's aircraft-agnostic, AI-powered software is purpose-built for military and civil programs, and is powering an expanding range of missions and aircraft, through hundreds of autonomous flights from test facilities across the globe. It operates as a single operating and reportable segment.